Processa Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Processa Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 7,920% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 96% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.1 times its market value (net cash). Higher than 89% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-35.9×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 67% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
1.1× cashCash, after subtracting all debt, is 1.1 times its market value (net cash).
Higher than 89% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Processa Pharmaceuticals, Inc. made a loss over the last year. Processa Pharmaceuticals, Inc. owes $1.15 for every $1 it owns. Processa Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossProcessa Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-16.40Processa Pharmaceuticals, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$5 MThe total market value of all of Processa Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), smaller than 93% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
NegativeProcessa Pharmaceuticals, Inc.'s net worth is negative ($0 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-464.2%Processa Pharmaceuticals, Inc. lost 464.2% of its shareholders' money over the last year, lower than 93% of Healthcare companies in United States.
Owes vs Owns
1.15×Processa Pharmaceuticals, Inc. owes $1.15 for every $1 it owns, so it owes more than it owns, higher than 90% of Healthcare companies in United States.
Dividend yield
NoneProcessa Pharmaceuticals, Inc. does not currently pay a dividend.
Profit growth
LossProcessa Pharmaceuticals, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashProcessa Pharmaceuticals, Inc. held $6 M more cash than debt (net cash) at Dec 2025.
Questions
What is Processa Pharmaceuticals, Inc.'s return on equity?
Processa Pharmaceuticals, Inc. lost 464.2% of its shareholders' money over the last year, lower than 93% of Healthcare companies in United States.
How much does Processa Pharmaceuticals, Inc. owe compared with what it owns?
Processa Pharmaceuticals, Inc. owes $1.15 for every $1 it owns, so it owes more than it owns, higher than 90% of Healthcare companies in United States.
Does Processa Pharmaceuticals, Inc. pay a dividend?
No. Processa Pharmaceuticals, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.